Global Duchenne muscular dystrophy sector hits US$2.19 billion in 2024, targeting US$6.64 billion by 2033 at 13.2% CAGR. Uncover trends in RNA-based treatments, Asia-Pacific's 8.1% regional growth, and key players like Sarepta Therapeutics driving exon 51 skipping solutions. https://finance.yahoo.com/news/duchenne-muscular-dystrophy-therapeutics-market-083800204.html